Results 211 to 220 of about 372,198 (288)

Who can safely discontinue lifelong follow‐up among patients with sporadic pheochromocytoma and paraganglioma?

Journal of Internal Medicine, Volume 299, Issue 5, Page 615-627, May 2026.
Abstract Background Current guidelines recommend at least 10 years of follow‐up for all pheochromocytoma and paraganglioma (PPGL) patients and lifelong monitoring for high‐risk individuals. Nonetheless, data identifying patients who may not require routine lifelong follow‐up are scarce. Methods Among 999 patients with PPGL, 703 who were non‐metastatic,
Min Jeong Park, Seung Shin Park, Won Woong Kim, Su‐Jin Kim, Yu‐Mi Lee, Kyu Eun Lee, Tae‐Yon Sung, Jae‐Kyung Won, Dong Eun Song, Jung‐Min Koh, Sara Talvacchio, Tamara Prodanov, Hussam Alkaissi, Karel Pacak, Seung Hun Lee, Jung Hee Kim   +15 more
wiley   +1 more source

Discordance Between Striatal Dopaminergic Imaging and Motor Performances in REM Sleep Behavior Disorder. [PDF]

Neurol Open Access
Zatti C, Miyagawa T, Kouchache T, Pelletier A, Lowe VJ, Criswell SR, Vernon CJ, St Louis EK, Fields JA, Gagnon JF, Kantarci K, Boeve BF, Postuma R.   +12 more
europepmc   +1 more source

Radioiodination of Two Carborane‐Based Dual Cyclooxygenase‐2/5‐Lipoxygenase Inhibitors and Their In Vitro and In Vivo Evaluation

ChemBioChem, Volume 27, Issue 7, 14 April 2026.
Two dicarbadodecaborane(12)‐based dual cyclooxygenase‐2/5‐lipoxygenase (COX‐2/5‐LO) inhibitors were 123I‐labeled. Refinement of labeling and formulation conditions and extensive in vitro characterization are presented. Cell uptake studies in COX‐2‐ and 5‐LO‐overexpressing cell lines showed COX‐2‐independent and partly 5‐LO‐dependent uptake.
Jonas Schädlich, Martin Ullrich, Cathleen Haase‐Kohn, Robert Wodtke, Sebastian Braun, Maximilian Molitor, Bettina Hofmann, Dieter Steinhilber, Klaus Kopka, Evamarie Hey‐Hawkins, Jens Pietzsch, Markus Laube   +11 more
wiley   +1 more source

Stepping onto the stage: reflections of community-based participatory researchers using Forum Theatre to address the challenges of living with diabetes while experiencing homelessness. [PDF]

Front Public Health
Tariq S, Grewal EK, Larsen M, Auger J, Booth R, Bowdridge B, Lawson J, Whaley A, Johnson NG, Reed T, Bassyouni H, Campbell DJT.   +11 more
europepmc   +1 more source

Modulating IDO1 and TDO Inhibition Through Structural Modification of Diaryl Hydroxylamines

ChemMedChem, Volume 21, Issue 7, 14 April 2026.
Diaryl hydroxylamines have emerged as promising scaffolds for targeting the tryptophan‐catabolizing enzymes indoleamine 2,3‐dioxygenase 1 (IDO1) and tryptophan 2,3‐dioxygenase (TDO), key drivers of tumor immune escape. Building on the reported dual IDO1/TDO inhibitory activity of O‐((3,5‐difluorophenyl)(phenyl)methyl)hydroxylamine, a series of diaryl ...
Angeliki S. Foscolos, Alexandros Pappas, Christos N. Petroulias, Anna Kapella, Georgia M. Prifti, Grigoris Zoidis, Minas Papadopoulos, Anastasia Mpakali, Aristeidis Chiotellis   +8 more
wiley   +1 more source

Perfusion-only Q-SPECT as a rule-out tool for CTEPH in resource-limited settings: a feasibility study on reducing unnecessary referrals to tertiary centers. [PDF]

BMC Pulm Med
Bilgic S, Vardaloglu I, Koroglu I, Karayel E.   +3 more
europepmc   +1 more source

The role of nuclear imaging in detection of coronary artery disease: a comprehensive review. [PDF]

Am J Transl Res
Zhou P, Wang F.
europepmc   +1 more source

Radiolabeled Iron-Based Nanomaterials for Cancer Diagnosis and Therapy. [PDF]

Int J Nanomedicine
Ma YX, Dai KL, Sun N, Zhang S.
europepmc   +1 more source

Quantitative performance of a 3D CZT and conventional SPECT/CT for Tb-161 imaging. [PDF]

EJNMMI Phys
Nuttens V, Imbert L, Delker A, Koole M.
europepmc   +1 more source